Becton, Dickinson and Company (BDX)
Will Becton Dickinson (BDX) Beat Estimates Again in Its Next Earnings Report?
Becton Dickinson (BDX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Becton, Dickinson - Stable Undervaluation In 1Q26, Upside Is There
Becton, Dickinson and Company is undervalued, trading at 12–13x P/E despite forecasted 7%–8% annual growth and improving fundamentals. BDX's sector-wide pressures are driven by cautious hospital spending, higher rates, and capital rotation into AI, but its core operations remain robust. BDX maintains a BBB rating, conservative leverage, a 2.78% dividend with 44+ years of increases, and is executing $2B in buybacks while retiring $2.1B in debt.
Here's Why You Should Retain BDX Stock in Your Portfolio Now
Becton, Dickinson's MedTech focus, innovation push and strategic partnerships support growth optimism, though reimbursement uncertainty remains a key concern.
BD Launches Elyra Thulium Fiber Laser System for Kidney Stone Care
BDX launches the Elyra Thulium Fiber Laser system to streamline kidney stone care and boost workflow flexibility for urology teams.
Becton, Dickinson and Company (BDX) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Becton, Dickinson and Company (BDX) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Becton, Dickinson and Company Q2 Earnings Call Highlights
Becton, Dickinson and Company NYSE: BDX reported fiscal second-quarter revenue and adjusted earnings ahead of its internal expectations, while management raised its full-year adjusted earnings outlook and said growth was broad-based across most of the portfolio.
Is the Options Market Predicting a Spike in Becton Dickinson Stock?
Investors need to pay close attention to BDX stock based on the movements in the options market lately.
Becton, Dickinson and Company (BDX) Q2 2026 Earnings Call Transcript
Becton, Dickinson and Company (BDX) Q2 2026 Earnings Call Transcript
Here's What Key Metrics Tell Us About Becton Dickinson (BDX) Q2 Earnings
While the top- and bottom-line numbers for Becton Dickinson (BDX) give a sense of how the business performed in the quarter ended March 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Becton Dickinson (BDX) Q2 Earnings and Revenues Surpass Estimates
Becton Dickinson (BDX) came out with quarterly earnings of $2.9 per share, beating the Zacks Consensus Estimate of $2.77 per share. This compares to earnings of $3.35 per share a year ago.
Becton Dickinson raises annual profit forecast on strength in drug delivery devices
Becton Dickinson raised its annual profit forecast on Thursday, riding strong demand for its drug-delivery devices and surgical equipment, and appointed Vitor Roque as its chief financial officer.
Seeking Clues to Becton Dickinson (BDX) Q2 Earnings? A Peek Into Wall Street Projections for Key Metrics
Beyond analysts' top-and-bottom-line estimates for Becton Dickinson (BDX), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended March 2026.
